Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C25H22N6O3 |
| Molecular Weight | 454.4806 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC#CC(=O)N1CC[C@H](C1)N2C(=O)N(C3=C(N)N=CN=C23)C4=CC=C(OC5=CC=CC=C5)C=C4
InChI
InChIKey=SEJLPXCPMNSRAM-GOSISDBHSA-N
InChI=1S/C25H22N6O3/c1-2-6-21(32)29-14-13-18(15-29)31-24-22(23(26)27-16-28-24)30(25(31)33)17-9-11-20(12-10-17)34-19-7-4-3-5-8-19/h3-5,7-12,16,18H,13-15H2,1H3,(H2,26,27,28)/t18-/m1/s1
Tirabrutinib (also known as ONO-4059 or GS-4059), a second-generation, enhanced-selectivity Bruton's tyrosine kinase inhibitor that demonstrated antitumor activity in preclinical models. Tirabrutinib participated in phase I clinical trial in patients with relapsed or refractory B-cell malignancies, where it was well tolerated and showed promising efficacy. In addition, tirabrutinib is involved in phase II clinical trials to study safety and efficacy in adults with Active Sjogren's syndrome and in adults with chronic lymphocytic leukemia. Besides the drug was studied for the treatment of Waldenstrom's macroglobulinemia and patients with refractory pemphigus.
Originator
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C124801
Created by
admin on Sat Dec 16 09:41:24 GMT 2023 , Edited by admin on Sat Dec 16 09:41:24 GMT 2023
|
||
|
FDA ORPHAN DRUG |
930322
Created by
admin on Sat Dec 16 09:41:24 GMT 2023 , Edited by admin on Sat Dec 16 09:41:24 GMT 2023
|
||
|
NCI_THESAURUS |
C129825
Created by
admin on Sat Dec 16 09:41:24 GMT 2023 , Edited by admin on Sat Dec 16 09:41:24 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
LXG44NDL2T
Created by
admin on Sat Dec 16 09:41:24 GMT 2023 , Edited by admin on Sat Dec 16 09:41:24 GMT 2023
|
PRIMARY | |||
|
100000172855
Created by
admin on Sat Dec 16 09:41:24 GMT 2023 , Edited by admin on Sat Dec 16 09:41:24 GMT 2023
|
PRIMARY | |||
|
C102876
Created by
admin on Sat Dec 16 09:41:24 GMT 2023 , Edited by admin on Sat Dec 16 09:41:24 GMT 2023
|
PRIMARY | |||
|
Tirabrutinib
Created by
admin on Sat Dec 16 09:41:24 GMT 2023 , Edited by admin on Sat Dec 16 09:41:24 GMT 2023
|
PRIMARY | |||
|
10320
Created by
admin on Sat Dec 16 09:41:24 GMT 2023 , Edited by admin on Sat Dec 16 09:41:24 GMT 2023
|
PRIMARY | |||
|
TIRABRUTINIB
Created by
admin on Sat Dec 16 09:41:24 GMT 2023 , Edited by admin on Sat Dec 16 09:41:24 GMT 2023
|
PRIMARY | MedKoo CAT NO.: 205914, CAS NO.: 1351635-67-0Description: ONO4059-Analog, CAS#1351635-67-0, is a potent and selective BTK inhibitor, and is a structural analogue of ONO-4059. ONO4059 is currently under clinical trials. Note: ONO4059 HCl has CAS#1439901-97-9, ONO4059 free base has CAS#1351636-18-4. (Last updated: 5/19/2016).Synonym: ONO4059-Analog, ONO 4059-Analog, ONO-4059-Analog, GS 4059-Analog, GS-4059-Analog, GS4059-Analog.IUPAC/Chemical Name: (S)-9-(1-acryloylpiperidin-3-yl)-6-amino-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one | ||
|
1351636-18-4
Created by
admin on Sat Dec 16 09:41:24 GMT 2023 , Edited by admin on Sat Dec 16 09:41:24 GMT 2023
|
PRIMARY | |||
|
54755438
Created by
admin on Sat Dec 16 09:41:24 GMT 2023 , Edited by admin on Sat Dec 16 09:41:24 GMT 2023
|
PRIMARY | |||
|
LM-62
Created by
admin on Sat Dec 16 09:41:24 GMT 2023 , Edited by admin on Sat Dec 16 09:41:24 GMT 2023
|
PRIMARY | |||
|
DB15227
Created by
admin on Sat Dec 16 09:41:24 GMT 2023 , Edited by admin on Sat Dec 16 09:41:24 GMT 2023
|
PRIMARY | |||
|
CHEMBL3544928
Created by
admin on Sat Dec 16 09:41:24 GMT 2023 , Edited by admin on Sat Dec 16 09:41:24 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
